Thus, our study highlights SPP1 as an essential target of BET inhibitors and has identified a novel mechanism by which BET inhibitors suppress melanoma progression via the noncanonical NF-κB/SPP1 pathway. This evidence concerns the gene SPP1 and melanoma.